Slameterol/fluticasone propionate - Mylan Pharma

Drug Profile

Slameterol/fluticasone propionate - Mylan Pharma

Alternative Names: MGR-001; Salmeterol xinafoate/fluticasone propionate - Mylan

Latest Information Update: 07 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mylan
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 05 May 2015 Phase-I clinical trials in Asthma (In adolescents, In adults) in United Kingdom (Inhalation)
  • 05 May 2015 Phase-I clinical trials in Chronic obstructive pulmonary disease (In adults, In adolescents) in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top